Viread Medication Summary
No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication?
This medication is described in FDA/DailyMed prescribing information. No separate FDA Medication Guide was found for this label. This summary is based on FDA/DailyMed prescribing information.
What is this medication used for?
VIREAD is a nucleotide analog HIV-1 reverse transcriptase inhibitor and an HBV reverse transcriptase inhibitor. VIREAD is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. ( 1) VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older. ( 1)
What should I know before taking it?
None.
What important warnings are listed?
Severe acute exacerbations of hepatitis have been reported in HBV-infected patients who have discontinued anti-hepatitis B therapy, including VIREAD. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy, including VIREAD. If appropriate, resumption of anti-hepatitis B therapy may be warranted [See Warnings and Precautions (5.1)] .
How is this medication usually taken?
VIREAD is available as tablets. Each tablet contains 300 mg of tenofovir DF, which is equivalent to 245 mg of tenofovir disoproxil. The tablets are almond shaped, white, film coated, and debossed with "GILEAD" and "4331" on one side.
What side effects are listed?
The following adverse reactions are discussed in other sections of the labeling: Severe Acute Exacerbation of Hepatitis [See Boxed Warning, Warnings and Precautions (5.1)] . New Onset or Worsening Renal Impairment [See Warnings and Precautions (5.2)] . Lactic Acidosis/Severe Hepatomegaly with Steatosis [See Warnings and Precautions (5.3)] . Bone Effects [See Warnings and Precautions (5.6)] . Immune Reconstitution Syndrome [See Warnings and Precautions (5.7)] .
What interactions are listed?
Tenofovir disoproxil fumarate increases didanosine concentrations. Dose reduction and close monitoring for didanosine toxicity are warranted. ( 7.2) Coadministration decreases atazanavir concentrations. When coadministered with VIREAD, use atazanavir given with ritonavir. ( 7.2) Coadministration of VIREAD with certain HIV-1 protease inhibitors or certain drugs to treat HCV increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity. ( 7.2) Consult Full Prescribing Information prior to and during treatment for important drug interactions. ( 7.2)
Where can I find the official prescribing information?
Review the full prescribing information on DailyMed: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fdae465-2c01-4030-a73c-fd2f13368453
⚠️ Disclaimer
This summary is for educational purposes only and is not medical advice. Always consult your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine. Read full medical disclaimer.